Launched in July 2025, this US-based Dropshipping business operates in the perimenopause and menopause telehealth niche, offering provider-led compounded GLP-1 medications and Hormone Replacement Therapy (HRT) to patients across all 50 states and Washington, D.C. Key strengths include a streamlined fulfillment model with no inventory handling, nationwide coverage through a network of partner pharmacies, and an established flow of customers from organic, referral, and direct traffic sources.

The business generates its revenue through sales of telehealth treatments, including compounded tirzepatide and semaglutide in injectable, oral dissolvable, and microdose formats, alongside HRT treatments. Traffic is approximately 51% Direct, 28% Organic Search, and 15% Referral, with a significant portion of direct traffic generated by affiliate websites operated by the seller. Three of these five affiliate sites are available to be included in the sale, while the seller will retain two that are personally branded around himself and his wife. Importantly, the affiliate revenue generated by the included sites has not been incorporated into the business P&L, giving a buyer the opportunity to benefit from additional revenue beyond the reported financial performance.

The operation does not hold inventory. A third-party telehealth and fulfillment partner manages the patient portal, 24/7 customer care, provider review process, prescriptions, and coordination with partner pharmacies, which ship medications directly to patients. The seller currently spends approximately 10–30 hours per week primarily on SEO, content creation, website improvements, and optional customer support oversight. With no paid advertising currently in use, there is substantial room to expand customer acquisition through Google Ads, Meta Ads, affiliates, influencers, further SEO content development, and additional affiliate sites. The established infrastructure, nationwide fulfillment capability, additional unreported affiliate revenue, and minimal reliance on paid acquisition make this an attractive opportunity for a buyer looking to scale an existing telehealth platform.